The enhancer element of hepatitis B virus (HBV) regulates the transcription of all HBV mRNA, including the pregenomic mRNA used during replication. This pregenomic mRNA is transcribed from the core gene promoter which is located 500 bp downstream from the HBV enhancer element. To examine the effect of the HBV enhancer on the activity of the core gene promoter, we constructed various plasmids containing different combinations of HBV enhancer and core gene promoter sequences regulating the expression of the chloramphenicol acetyltransferase gene. When the HBV enhancer was positioned immediately adjacent to the core gene promoter, the enhancer increased the activity of the core gene promoter nearly 30-fold. In contrast, the HBV enhancer only modestly stimulated the core gene promoter (less than threefold) at its native position in the HBV genome. This weak HBV enhancer activity was due to a DNA sequence located between the enhancer and the core gene promoter and not due to the increased distance between the enhancer and the core gene promoter. Competition experiments demonstrated that a trans-acting factor(s) bound this sequence and repressed the enhancer. This DNA sequence contains the C/EBP, AP-1 and NF-1 regulatory sites. No inhibition of enhancer activity was observed when only the AP-1 and C/EBP sites were present. Repression of the HBV enhancer was not detected when the NF-1 site was disrupted, indicating that the NF-1 site was involved in the suppression of the HBV enhancer.
Introduction
The Hepadnaviridae are a group of hepatotropic DNA viruses that share a common genomic structure and replication cycle (Ganem & Varmus, 1987; Tiollais et al., 1985) . The prototype virus of the Hepadnaviridae is hepatitis B virus (HBV), whose only natural host is man (Gust et al., 1986) . The genome of HBV is approximately 3-2 kb in length and contains four major open reading frames (ORFs), encoding the core, surface, DNA polymerase and X proteins (Ganem & Varmus, 1987) . The HBV DNA polymerase ORF is the largest HBV gene, encompassing approximately 80~ of the genome and overlapping every other viral gene (Bavand & Laub, 1988) . The HBV polymerase has reverse transcriptase and RNase H activities (Radziwill et al., 1990) . It also serves as the terminal protein which initiates replication (Bartenschlager & Schaller, 1988) and is required for encapsidation of the viral genome (Hirsch et al., 1990) . The core protein and the surface protein are the major proteins of the viral capsid and envelope, respectively (Ganem & Varmus, 1987) . In addition to their structural functions, proteins expressed from both the core antigen gene (Twu et al., 1988; Twu & Schloemer, 1989 ) and the t Present address: Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana 46202, U.S.A. surface antigen gene (Caselmann et al., 1990; have been shown to regulate gene expression. The X protein regulates the transcription of HBV genes and a variety of cellular and viral genes (Spandau & Lee, 1987 Seto et al., 1989; Siddiqui et al., 1989; Twu & Schloemer, 1987; Zahm et al., 1988) .
Several transcriptional promoter regions have been identified in the HBV genome. They initiate transcription of various HBV genes and are regulated by the HBV enhancer (Antonucci & Rutter, 1989; Honigwachs et al., 1989; Yaginuma & Koike, 1989) . The HBV enhancer, which is located between the end of the surface antigen gene and the beginning of the X gene, binds both ubiquitous and tissue-specific transcription factors that control the expression of HBV genes (Antonucci & Rutter, 1989; Ben-Levy et al., 1989; Jameel & Siddiqui, 1986; Ostapchuk et al., 1989; Patel et al., 1989; Shaul & Ben-Levy, 1987; Shaul et al., 1985) .
The replication scheme utilized by hepadnaviruses is unique to animal viruses. HBV replication requires the reverse transcription of a viral mRNA (called the pregenome; Ganem & Varmus, 1987) . Transcription of the pregenomic mRNA initiates at the core gene promoter, and all of the replication steps after the transcription of the pregenomic mRNA occur within viral capsid particles (Ganem & Varmus, 1987) . Since HBV replicates through the pregenomic mRNA, the transcription of which is regulated by the HBV enhancer, its activity within any given cell can determine the extent of HBV replication within that cell. The HBV enhancer is most active in hepatic cells; this tissuespecific nature of the HBV enhancer may contribute to the hepatotropic property of the virus.
Previous results generated in both our laboratory (D. F. Spandau, unpublished observations) and others (Honigwachs et al., 1989; Bulla & Siddiqui, 1988) have suggested that the HBV enhancer and core gene promoter in the native context of the HBV genome do not function to their full capacity. We explored this phenomenon by subcloning the HBV enhancer and the core gene promoter into different DNA environments and then determining the activity of the enhancer and the core gene promoter in those environments. We found that the activity of the HBV enhancer was inhibited by a sequence located between the HBV enhancer and the core gene promoter.
Methods
Plasmid construction. The restriction maps of the plasmids pCP, pHECP and pZE8cat are shown in Fig. 1 (a) . pCP was created by inserting the 100 bp StuI-FspI restriction fragment from pUC9/HBV (Spandau & Lee, 1988) into the Sinai site of the chloramphenicol acetyltransferase (CAT) vector pZH8cat which is identical to pZE8cat but with an inverted multiple cloning site (MCS). In this manner, the expression of cat is regulated by the minima[ HBV core gene promoter. The plasmid pHECP was constructed by cloning the 1800 bp EcoRIFspI fragment from pUC9/HBV between the EcoRI and StuI sites of pZH8cat. The cat gene on pHECP was controlled by the HBV enhancer and core gene promoter. The plasmid pZE8cat was cloned using the following protocol. The simian virus 40 (SV40) early promoter, the cat gene and the SV40 polyadenylation site were isolated from pSV2cat (Gorman et al., 1982) as a SphI-BamHI fragment. The vector pTZ18U was linearized atthe EcoRl site. The cohesive termini of both the insert DNA and the vector DNA were changed to blunt ends using the Klenow enzyme of Escherichia coli DNA polymerase I.
The two different blunt-ended fragments were then ligated using T4 DNA ligase. In the correct orientation, the MCS of pTZ18U was located immediately upstream from the SV40 early promoter. In subsequent plasmid constructions using pZE8cat, the SV40 early promoter could be deleted by cleaving with StuI and an enzyme clearing at any restriction site within the MCS. The plasmid pHECPX494 was constructed by deleting the Ball-StuI fragment from pHECP and replacing it with a 493 bp FnuDII fragment derived from pBR322. Similarly, the plasmid pHECPX327 was constructed by deleting the NcoI-StuI fragment from pHECP and replacing it with a 330 bp FnuDII fragment derived from pBR322.
Transfections and CAT assays. Cell cultures were transfected with plasmid DNA using the calcium phosphate precipitation method as previously described (Spandau & Lee, 1988) . Assays for CAT activity were performed as described (Spandau & Lee, 1988) . a4C-labelled chloramphenicol species were quantitatively determined using an AMBIS Radioanalytic Imaging System (AMBIS Systems) and the percentage of acetylated chloramphenicol was calculated. On the left side of the figure is a map of the HBV genome (thick box) linearized at the unique EcoRI site. The location of the major ORFs are shown as lines above the genomic map, and a region of the HBV enhancer is enlarged below the genomic map. The enhancer elements defined by Shaul & Ben-Levy (1987) are labelled above the enlarged enhancer fragment. Subfragments of the HBV enhancer used in this study are depicted below the enhancer map, and the names of the subfragments used in this paper are listed in the first column adjoining the illustration. The restriction site used for the isolation of each enhancer fragment is shown on the enhancer map. These enhancer fragments were used to create the plasmids listed in the remaining columns. The enhancer fragments were cloned into the MCS of pUC19 (creating the pUC-HE series), pZE8cat (creating the pHE-SVP series) or pCP (creating pHE-CP 
Results and Discussion

The effect of the H B V enhancer on the activity of the H B V core gene promoter at its native location in the HB V genome
To investigate the effect of the HBV enhancer on the core gene promoter, we cloned the 244 bp HpaI-Bali fragment (called HE2, Fig. 1 (Shaul & Ben-Levy, 1987; BenLevy et al., 1989) . The E element is essential for the activity of the HBV enhancer, whereas the other elements modulate the activity of the enhancer. In this context, the HBV enhancer increased transcription from the core gene promoter by 29-fold ( Fig. 2 ; compare pCP and pHE2-CP). However, in its native position (Fig. 2,  pHECP) , the HBV enhancer stimulated the expression of the core gene promoter by only 2.5-fold. We hypothesized that a DNA sequence located between the enhancer and the core gene promoter (the 485 bp BaliStuI fragment) was quenching the signal from the HBV enhancer to the core gene promoter. A deletion analysis within this region was performed to localize this sequence. To keep the distance between the enhancer and core gene promoter constant, the deleted HBV sequences were replaced with a DNA fragment of similar size from pBR322. A 327 bp deletion was made between the NcoI and StuI sites of the HBV genome and replaced with a 330 bp FnuDII fragment from pBR322. This recombinant plasmid was referred to as pHECPX327 (Fig. 2) . This deletion did not relieve the suppression of the HBV enhancer (Fig. 2) . When a 485 bp BalI-StuI fragment of HBV DNA was deleted and replaced with a 494 bp FnuDII fragment from pBR322 (designated pHECPX494), the HBV enhancer stimulated the core gene promoter approximately 10-fold (Fig. 2) . Therefore, the BalI-StuI deletion partially relieved the suppression of the HBV enhancer. Based on this deletion analysis, we speculated that the sequence responsible for the suppression of the HBV enhancer was located between the Bali and the NcoI sites (Fig. 1) .
The effect of titration with a sequence jrom the H B V enhancer on the activity of the native H B V enhancer and core gene promoter
To localize the DNA sequence responsible for the suppression of the HBV enhancer, competition experi- merits were performed. These experiments were based on the assumption that the inhibition of the HBV enhancer was due to the binding of a diffusible transacting repressor(s) to or close to the HBV enhancer. This hypothesis was tested by cotransfecting pHECP and a competing plasmid containing only an HBV enhancer sequence. When the repressor binds the competing HBV enhancer sequence, less repressor will be available to bind the sequence that regulates the CAT gene on pHECP, resulting in higher CAT gene expression. HepG2 cells were cotransfected with pHECP and 0, 1, 5 or 10 molar equivalents of pUC-HE1 (previously referred to as pEN1 ; Pei & Shih, 1990) , containing the 192 bp EcoRI-SphI fragment of the HBV enhancer (Fig.  3) . When 10 molar equivalents of pUC-HE1 was cotransfected with pHECP, the activity of the HBY enhancer and core gene promoter was 6.2-fold higher than that without pUC-HE1. This result demonstrated that the HE1 fragment bound a factor that inhibited the activation of the core gene promoter by the HBV enhancer. As a control, pHE2-CP was used in identical competition experiments because the HE2 fragment did not contain sequences that inhibited the activity of the HBV enhancer (Fig. 2) . When pHE2-CP was cotransfected with pUC-HE1, CAT gene expression was reduced suggesting that a positive transcriptional factor(s) was titrated by pUC-HE1. This result indicates Fig. 3 . The effect of increasing quantities of competing HBV enhancer sequences on the activity of the HBV enhancer in HepG2 cells, pHECP (©) and pHE2-CP (Q) were cotransfected with increasing amounts of pUC-HE1 DNA in HepG2 cells as described in Fig. 2 . The concentration of pUC-HEI was adjusted so that 1, 5 or 10 gene (or molar) equivalents were cotransfected with each of the reporter plasmids. Quantitative analyses of CAT activity were performed as described in Fig. 2 . Fold change in CAT activity due to the competing pUC-HEI DNA was calculated by comparing the CAT activity of cotransfected cells with that of cells in the absence of competing DNA. The transfection efficiency was monitored by extracting the low Mr DNA from transfected cells using the method described by Hirt (1967) . The extracted DNA was linearized by appropriate restriction enzymes, separated on a 1 ~ agarose gel, transferred to a nylon membrane, and probed with 32p-labelled DNA derived from the parent plasmids. Only transfections that demonstrated equal amounts of reporter plasmids as well as the appropriate levels of competing plasmids were assayed for CAT activity.
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that the sequence in the HE1 fragment that bound the repressor was not present in the HE2 fragment. Therefore, we speculated that the repressor binds a sequence in the 3' end of the HE1 fragment that is missing in the HE2 fragment (Fig. 1) .
The titration of the repressor of the HBV enhancer by a 65 bp fragment
To determine whether the repressor bound at the 3'-terminal end of the HE1 fragment, the 65 bp BstEIISphI fragment (HE3) was cloned (pUC-HE3; Fig. 1 b) and used in competition experiments. The HE3 fragment was also cleaved with Bali to generate the 16 bp BaliSphI (HE4) and 49 bp BstNI-Bali (HE5) fragments. The plasmids containing these two fragments were designated pUC-HE4 and pUC-HE5, respectively (Fig. 1 b) . These plasmids were used in titration experiments with pHECP as previously described. Only pUC-HE3 titrated the repressor of the HBV enhancer (Fig. 4) . No change in gene expression directed by the HBV enhancer was observed when pHECP was cotransfected with pUC-HE4 or pUC-HE5. Since pUC-HE3 titrated the repressor as well as pUC-HE1 (Fig. 4) , the DNA sequence that was required to bind the inhibitor of the HBV enhancer was contained within the HE3 (BstNI-SphI) fragment. Neither the HE4 (BstNI-BalI) nor the HE5 (BalI-SphI) subfragments contained sufficient DNA sequences to titrate the inhibitor. This result implied that the Bali restriction endonuctease, which was used to create HE4 and HE5, cleaved the sequence that was required for repressor activity.
The suppressive effect of the HE3 fragment on the expression from a heterologous promoter
To determine whether the repressor that bound the HE3 fragment could repress a heterologous promoter, the HBV enhancer fragments HE1, HE2 and HE3 were cloned into pZE8cat which contains the SV40 early promoter regulating the CAT gene (Fig. I a) , creating the plasmids pHE1-SVP, pHE2-SVP and pHE3-SVP, respectively ( Fig. 1 b) . These plasmids were then transfected into HepG2, PLC/PRF/5 (human hepatoblastoma) or iCV-1 (simian kidney) cells. Both the HE1 and the HE2 enhancer fragments stimulated the expression of the SV40 early promoter in HepG2, PLC/PRF/5 and CV-1 cells (Fig. 5) . In contrast, the HE3 fragment caused a decrease in the activity of the SV40 early promoter in all three cell lines tested. This repression of the SV40 early promoter was most obvious in the non-liver, non-human CV-1 cells. These results indicated that the inhibitor which binds to the HE3 fragment could also inhibit a heterologous promoter and was not specific for the HBV core gene promoter.
The requirement o f an intact NF-l-binding site for the inhibition o f H B V enhancer activity
The binding sites of transcriptional factors on the HBV enhancer have been studied extensively (Ben-Levy et al., 1989; Faktor et al., 1990; Ostapchuk et al., 1989; Patel et al., 1989; Shaul & Ben-Levy, 1987) . The HE3 fragment contains recognition sequences for three transcriptional factors: C/EBP, AP-1 and NF-1 ( Fig. 6 ; Ben-Levy et al., 1989; Faktor et al., 1990; Landschulz et al., 1988; Patel et al., 1989) . Since the HE3 fragment could titrate the inhibitor of the HBV enhancer in competition experiments (Fig. 4) and down-regulate the expression of a heterologous promoter (Fig. 5) , the proteins that bind these sites may be responsible for the repression of the Ben-Levy et al., 1989; Faktor et al., 1990) . The HBV DNA sequences present in pUC-HE3, pUC-HE4 and pUC-HE5 are given beneath the nucleotide sequence. The BstNI, Bali and SphI sites are located at HBV genome positions 1165, 1214 and 1234 of the HBV adw2 subtype used in this study (Cummings et al., 1980) .
enhancer. When the HE3 fragment was cleaved within the NF-1 site (Fig. 6) , neither of the resulting HE4 or HE5 fragments could titrate the repressor (Fig. 4) . Therefore, disruption of the NF-1 site resulted in the elimination of the repressor activity of the HE3 fragment. The importance of the NF-1 site in the inhibition of the HBV enhancer was also demonstrated by the lack of a suppressive effect of the HE2 fragment (Fig. 2, 3 and 5), which does not contain an intact NF-1 site.
The observation that the HE5 fragment, which contains the C/EBP and AP-1 sites, did not relieve the suppression of the HBV enhancer in competition experiments indicated that the C/EBP and AP-1 sites by themselves did not bind the repressor. Pei & Shih (1990) recently reported that increased levels of the C/EBP protein within HepG2 cells resulted in a decrease in the number of HBV transcripts from the core and surface gene promoters. In competition experiments similar to those reported in this paper, they also observed an increase in HBV gene transcription with increasing concentrations of pUC-HE1 (pEN1). They interpreted this as a titration of the C/EBP protein by pUC-HE1. Using the HE5 fragment which contains both the C/EBP and AP-1 binding sites as the competing D N A (pUC-HE5), we did not titrate the repressor activity (Fig. 4) . Therefore, the repression of the HBV enhancer may be a cooperative effect between the proteins that bind the C/EBP and NF-1 sites rather than independent activities of either of these proteins. The juxtaposition of C/EBP and NF-1 sites is also seen in the liver-specific rat albumin gene enhancer. In this context, the NF-1 site has been suggested to function as a repressor-binding site (Paonessa et al., 1988) . AP-1 sites have also been implicated in the negative regulation of enhancers (Hay et al., 1989) , depending on what nuclear factors are present within a cell.
The function of the repressor may vary depending on the type and concentration of transcription factors present in a particular cell and may affect the replication of HBV. In cells which are not permissive for HBV replication, the suppression of the HBV enhancer would prevent HBV from replicating. The observation that the suppressive effect of the HE3 fragment was greatest in a non-human, non-liver cell line (CV-1) supports this hypothesis. In cells which are permissive for HBV replication, there must be a mechanism to relieve the repression of the HBV enhancer and to allow transcription of the pregenomic mRNA. Koikeda et al. (1990) have reported that an NF-l-like protein binds the adenovirus 12 E1A enhancer and preferentially directs transcription from only one of two promoters that are located downstream from the enhancer. In the absence of this factor, the transcriptional activity of both promoters is equal. The factor that binds the NF-1 site of the HBV enhancer may act similarly and affect the expression of the various HBV promoters at different stages of HBV replication.
Conclusions
In their native position within the HBV genome, the HBV enhancer and core gene promoter function less efficiently than when the HBV enhancer is placed immediately upstream from the core gene promoter. Our results suggest that this down-regulation in activity is due to inhibition of the HBV enhancer. The inhibition of the HBV enhancer could be relieved by cotransfection of a 65 bp subfragment (HE3) of the HBV enhancer, indicating that the inhibition was due to a trans-acting repressor molecule which acted within the HE3 fragment. Disruption of the NF-l-binding site within the HE3 fragment abolished the ability of the competing DNA fragments to titrate the repressor molecule. The presence of intact C/EBP-and AP-l-binding sites was insufficient to titrate the repressor. Therefore, we propose that the repressor binds to or acts through the NF-l-binding site and that the repression of the HBV enhancer may require the interaction of proteins binding to C/EBP, AP-1 and NF-1 sites. Although the NF-1-binding sequence was necessary for the repressor activity, we have no evidence to suggest that the factor responsible for the repression is the NF-1 protein. In fact, Patel et al. (1989) have suggested that this sequence binds a protein related to NF-1 but not NF-1 itself.
